Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial

Muskiet M. H. A.; Bunck M. C.; Heine R. J.; Corner A.; Yki-Jarvinen H.; Eliasson B.; Joles J. A.; Diamant M.; Tonneijck L.; van Raalte D. H.

首页> 外文期刊>Diabetes research and clinical practice >Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial

【24h】

Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial

机译：与2型糖尿病患者的滴定胰岛素狼醋相比，每日两次每日两次，不影响肾功能或白蛋白尿尿素：52周随机试验的后HOC分析

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

摘要
著录项
引文网络
相似文献
相关主题

摘要

Aims: To compare the effects of long-term treatment with the GLP-1RA exenatide twicedaily versus titrated insulin glargine (iGlar) on renal function and albuminuria in type 2 diabetes (T2DM) patients.

机译：目的：比较长期治疗与GLP-1RA exenatide Twicedaily的影响Twicedaily与肾功能和2型糖尿病（T2DM）患者的肾功能和白蛋白尿中滴定的胰岛素狼吞虎咽（Iglar）。

著录项

来源
《Diabetes research and clinical practice》 |2019年第2019期|共9页
作者
Muskiet M. H. A.; Bunck M. C.; Heine R. J.; Corner A.; Yki-Jarvinen H.; Eliasson B.; Joles J. A.; Diamant M.; Tonneijck L.; van Raalte D. H.;
展开▼
作者单位

Univ Amsterdam Med Ctr Diabet Ctr Amsterdam Netherlands;

Univ Amsterdam Med Ctr Diabet Ctr Amsterdam Netherlands;

Univ Amsterdam Med Ctr Diabet Ctr Amsterdam Netherlands;

Univ Helsinki Res Programs Unit Diabet &

Obes Helsinki Finland;

Univ Helsinki Res Programs Unit Diabet &

Obes Helsinki Finland;

Sahlgrens Univ Hosp Lundberg Lab Diabet Res Gothenburg Sweden;

Univ Med Ctr Dept Nephrol &

Hypertens Utrecht Netherlands;

Univ Amsterdam Med Ctr Diabet Ctr Amsterdam Netherlands;

Univ Amsterdam Med Ctr Diabet Ctr Amsterdam Netherlands;

Univ Amsterdam Med Ctr Diabet Ctr Amsterdam Netherlands;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类内分泌腺疾病及代谢病;
关键词
GLP-1 receptor agonist; Exenatide; Insulin glargine; Albuminuria; Glomerular filtration rate; Diabetic kidney disease; Renoprotection; Type 2 diabetes mellitus;

机译：GLP-1受体激动剂;exenatide;胰岛素冰壶;白蛋白尿;肾小球过滤速率;糖尿病肾病;无润蛋白;2型糖尿病;

相似文献

外文文献
中文文献
专利

1. Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial [J] . Muskiet M. H. A., Bunck M. C., Heine R. J., Diabetes research and clinical practice . 2019,第期

机译：与2型糖尿病患者的滴定胰岛素狼醋相比，每日两次每日两次，不影响肾功能或白蛋白尿尿素：52周随机试验的后HOC分析
2. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. [J] . Diamant M, Van Gaal L, Stranks S, The Lancet . 2010,第9733期

机译：每周一次艾塞那肽与甘精胰岛素的胰岛素滴定比定为2型糖尿病患者的靶标（DURATION-3）：一项开放标签的随机试验。
3. Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized, open-label, controlled trial [J] . Jie Zhang, Tong-Zhang Xian, Ming-Xiao Wu, Cardiovascular Diabetology . 2020,第1期

机译：两次exenatide和胰岛素对2型糖尿病患者颈动脉内膜介质厚度的影响的比较：52周随机化，开放标签，受控试验
4. Switching to insulin glargine 300 U/mL from other basal insulin analogues provides less 24-hour glucose variability in hospitalized patients with type 1 diabetes [C] . V.V. Klimontov, E.A. Koroleva, O.N. Fazullina International Multiconference Bioinformatics of Genome Regulation and StructureSystems Biology . 2018

机译：从其他基础胰岛素类似物转换为甘精胰岛素300 U / mL可使住院的1型糖尿病患者的24小时葡萄糖变异性降低
5. A 4-month randomized controlled clinical trial of adjuvant Exenatide or Pramlintide versus insulin alone in pediatric type 1 diabetes mellitus: Effect on glycemic control. [D] . Withycombe, Sarah Elizabeth. 2010

机译：儿科1型糖尿病患者中艾塞那肽或普兰林肽与单独使用胰岛素的4个月随机对照临床试验：对血糖控制的影响。
6. Comparison of the effects of twice-daily exenatide and insulin on carotid intima-media thickness in type 2 diabetes mellitus patients: a 52-week randomized open-label controlled trial [O] . Jie Zhang, Tong-Zhang Xian, Ming-Xiao Wu, 2020

机译：每天两次艾塞那肽和胰岛素对2型糖尿病患者颈动脉内膜中层厚度的影响比较：一项为期52周的随机开放标签对照试验
7. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes [O] . 2008

机译：一项随机的，为期52周的针对治疗的目标试验，比较了初次使用胰岛素的2型糖尿病患者中将地特胰岛素和甘精胰岛素作为降糖药物的附加药物时的情况

Exenatide twice-daily does not affect renal function or albuminuria compared to titrated insulin glargine in patients with type 2 diabetes mellitus: A post-hoc analysis of a 52-week randomised trial

摘要

著录项

引文网络

相似文献

相关主题

期刊订阅